Isis Pharmaceuticals (ISIS) 66.37 $ISIS
Idera Pharmaceuticals: Is The Writing On The Wall?
Sagacious Investor - at Seeking Alpha - Fri Apr 24, 7:02AM CDT
IDRA: 3.32 (-0.12), ISIS: 66.37 (-1.38)
Isis Pharmaceuticals' ISIS-TTR Effective in Extension Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 5:21PM CDT
Isis Pharmaceuticals, Inc. (ISIS) announced positive data from an extension study on ISIS-TTR for familial amyloid polyneuropathy.
BIIB: 401.71 (-28.57), ISIS: 66.37 (-1.38), AVEO: 1.92 (-0.08), GSK: 46.59 (+0.28)
Alnylam Strengthens Its Clinical Case Once Again
Stephen Simpson, CFA - at Seeking Alpha - Thu Apr 23, 10:27AM CDT
ALNY: 119.01 (+0.29), ISIS: 66.37 (-1.38), PFE: 35.27 (-0.09), ALXN: 180.08 (-4.50)
Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis
PR Newswire - Wed Apr 22, 3:06PM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive data from an ongoing open-label extension (OLE) study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). FAP patients completing the ongoing Phase 3 study are eligible to enroll in this OLE study in which all patients receive ISIS-TTRRx. An analysis conducted on the first group of patients to reach three months of treatment in the OLE study showed a reduction in transthyretin (TTR) protein levels up to 92 percent with a median reduction of 78 percent compared to patients' baseline TTR levels at entry into the Phase 3 study. Patients continue to be enrolled as they complete dosing in the Phase 3 study. These data will be presented today at the American Academy of Neurology meeting in Washington, DC.
ISIS: 66.37 (-1.38)
How to Invest Money in Biotech
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 19, 1:02PM CDT
Source: Isis Pharmaceuticals, Facebook. I believe it goes without saying that the biotechnology sector is one of the most unique sectors in the stock market. Whereas most industries (and the companies within those industries) are valued based on...
ISIS: 66.37 (-1.38), GILD: 103.69 (-1.52), XBI: 233.86 (-2.86), CELG: 118.71 (+2.62)
Johnson & Johnson's Earnings: The Good, The Bad and The Ugly
George Budwell, The Motley Fool - Motley Fool - Thu Apr 16, 10:59AM CDT
After a stellar 2014, Johnson & Johnson 's stock has lagged behind the broader market this year: To gain some insight into this top healthcare stock's weakness so far in 2015, let's dig into the company's first-quarter earnings,...
ACHC: 72.60 (+0.22), JNJ: 101.08 (+0.62), PCYC: 256.59 (-0.51), ISIS: 66.37 (-1.38), SGEN: 37.14 (-0.36), GILD: 103.69 (-1.52), PFG: 51.62 (+0.31), ABBV: 66.07 (+1.82), PBYI: 222.10 (-6.35)
Top 50 Big Biotech Partnering and M&A Deal Trends Report 2015
M2 - Thu Apr 16, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxqgzt/top_50_big) has announced the addition of the "Top 50 Big Biotech Partnering and M&A Deal Trends" report to their offering. The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies. Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits: - Detailed partnering activity profiles for each of the top 50 big biotech companies - Over 300 charts showing a company's dealmaking activity since 2009, allowing quick identification potential partners - Partnering therapy focus revealed - Partnering activity since 2010 - number of deals per year - Full listing of partnering deals - Activity by deal type - Activity by industry sector - Activity by phase of development - Activity by technology type - Activity by therapeutic area - Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available - Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents - Understand the key deal terms the company has agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Big biotech top 50 dealmaking activity Chapter 3 - Top big biotech deals by value Chapter 4 - Submitting Opportunities to Big biotech Chapter 5 - Forthcoming big biotech partnering events Chapter 6 - Big Biotech Company Profiles - 30 of the 50 companies - Acorda Therapeutics - Actavis - Actelion - Alexion Pharmaceuticals - Alkermes - Allergan - Amgen - Bavarian Nordic - Biocon - Biogen Idec - BioMarin Pharmaceuticals - Celgene - CSL - Cubist - Genmab - Gilead Sciences - Isis Pharmaceuticals - Jaxx Pharmaceuticals - LFB Group - Medivation - PDL BioPharma - Pharmacyclics - Questcor Pharmaceuticals - Regeneron Pharmaceuticals - Roche - Salix Pharmaceuticals - SciClone Pharmaceuticals - Seattle Genetics - Shire - Vertex Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/dxqgzt/top_50_big
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), SLXP: 172.96 (+0.15), AMGN: 167.91 (-1.26), ACOR: 33.12 (-0.38), ALKS: 62.26 (-1.19), PDLI: 7.02 (-0.09), AGN: 240.22 (+2.88), ISIS: 66.37 (-1.38), GILD: 103.69 (-1.52), ALXN: 180.08 (-4.50), SCLN: 8.96 (-0.13), REGN: 480.09 (+0.01), CELGZ: 2.76 (-0.12)
3 Biotech Stocks That May Disappear Before 2020
Brian Orelli, Sean Williams, and George Budwell, The Motley Fool - Motley Fool - Wed Apr 15, 7:59AM CDT
Biotechs come and go. It's rare to see a biotech as old as Amgen , which is celebrating its 35th anniversary this year. Most biotechs get acquired, or fall short and go bankrupt long before then. We asked our team of biotech experts to find a...
INO: 10.35 (-0.25), ISIS: 66.37 (-1.38), AZN: 71.79 (-1.34), AMGN: 167.91 (-1.26), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22), EXEL: 3.08 (-0.02)
Critical Alerts For GoPro, Shire, Isis Pharmaceuticals, Whiting Petroleum and athenahealth Released By InvestorsObserver
PR Newswire - Fri Apr 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, SHPG, ISIS, WLL and ATHN.
GPRO: 44.73 (-1.35), WLL: 35.62 (-1.01), ISIS: 66.37 (-1.38), SHPG: 255.11 (-0.26), ATHN: 125.30 (+3.30)
Isis Pharmaceuticals to Present at Upcoming Investor Conferences
PR Newswire - Fri Apr 10, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:
ISIS: 66.37 (-1.38)
SmarTrend Watching for Potential Pullback in Shares of Isis Pharmaceuticals After 3.32% Gain
Comtex SmarTrend(R) - Thu Apr 09, 4:11PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $61.52 to a high of $64.10. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $63.90 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 66.37 (-1.38)
Jim Cramer -- If You're Not in Biotech for the Long Haul, Hit the Road
at The Street - Wed Apr 08, 5:14AM CDT
Today's a good day for all who own biotech to reassess. Ask yourself, do you know why you own it?
RH: 91.89 (+0.20), ISIS: 66.37 (-1.38), REGN: 480.09 (+0.01)
Isis And Durect Foray Into NASH; Durect Is The Better Bet
Clinically Sound Investor - at Seeking Alpha - Mon Apr 06, 7:23PM CDT
ISIS: 66.37 (-1.38), DRRX: 2.11 (-0.46)
Is Isis Pharmaceuticals (ISIS) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 7:53AM CDT
One stock that might be an intriguing choice for investors right now is Isis Pharmaceuticals as this security in the pharmaceutical space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
ISIS: 66.37 (-1.38)
ISIS Pharmaceuticals (ISIS) Strong On High Relative Volume Today
at The Street - Fri Mar 27, 9:05AM CDT
Trade-Ideas LLC identified ISIS Pharmaceuticals (ISIS) as a strong on high relative volume candidate
ISIS: 66.37 (-1.38)
Earnings Coverage - Isis Pharma
PR Newswire - Fri Mar 27, 7:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ISIS: 66.37 (-1.38)
'Mad Money' Lightning Round: Buy, Buy, Buy ConocoPhillips
at The Street - Thu Mar 26, 5:00AM CDT
Cramer likes Ryanair, Pfizer and MeadWestvaco but is avoiding Rovi Corporation, Five Prime Therapeutics and Avon Products.
RYAAY: 67.00 (+0.51), AVP: 9.02 (+0.03), ISIS: 66.37 (-1.38), MWV: 47.50 (+0.41), PFE: 35.27 (-0.09), IP: 53.67 (+0.79), COP: 67.51 (-0.75), VG: 4.90 (-0.04), URI: 96.64 (-1.89), ROVI: 19.48 (+0.18), FPRX: 24.20 (-0.26)
Pfizer Is An Outright Buy - Cramer's Lightning Round (3/25/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Thu Mar 26, 3:55AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 25. Bullish Calls: Isis Pharmaceuticals (NASDAQ: ISIS ): "My take is this: It is going to go even lower because it's part of the highest...
AVP: 9.02 (+0.03), PFE: 35.27 (-0.09), IP: 53.67 (+0.79), COP: 67.51 (-0.75), PCLN: 1,233.09 (+11.99), VG: 4.90 (-0.04), NFLX: 558.40 (-0.66), RYAAY: 67.00 (+0.51), ISIS: 66.37 (-1.38), MWV: 47.50 (+0.41), FPRX: 24.20 (-0.26), ROVI: 19.48 (+0.18), URI: 96.64 (-1.89)
Jim Cramer's 'Mad Money' Recap: This Market Has Gotten Too Hot
at The Street - Wed Mar 25, 7:13PM CDT
As Cramer predicted, biotechs have started to cool. What should investors do next? Nothing, he advises.
73.54 (+0.34), UTX: 116.16 (-1.10), KRFT: 87.57 (-0.81), PAH: 27.18 (-0.76), INTC: 32.08 (-0.27), PVH: 104.43 (-0.86), VG: 4.90 (-0.04), DFS: 58.39 (-0.28), RYAAY: 67.00 (+0.51), PAYX: 49.23 (-0.28), SONC: 30.83 (-0.21), MWV: 47.50 (+0.41), COST: 148.12 (+0.82), ABBV: 66.07 (+1.82), MMP: 82.31 (+0.61), REGN: 480.09 (+0.01), CSCO: 28.82 (+0.15), URI: 96.64 (-1.89), ROVI: 19.48 (+0.18), AVP: 9.02 (+0.03), KR: 71.70 (+0.77), FB: 81.53 (-0.88), IP: 53.67 (+0.79), PFE: 35.27 (-0.09), DIS: 109.53 (+0.53), COP: 67.51 (-0.75), AMGN: 167.91 (-1.26), WFC: 54.70 (-0.16), DENN: 11.69 (+0.05), CELG: 118.71 (+2.62), WWAV: 45.60 (-0.08), ISIS: 66.37 (-1.38), FPRX: 24.20 (-0.26)
Isis Pharmaceuticals Reports Phase I Data on Lipid Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 3:51PM CDT
Isis Pharmaceuticals, Inc. (ISIS) announced encouraging results from a phase I study on pipeline candidate ISIS-ANGPTL3Rx.
ISIS: 66.37 (-1.38), ANIP: 70.26 (-1.52), HZNP: 31.75 (+0.97), SNY: 51.75 (-0.01)
Idera Pharmaceuticals: Is The Writing On The Wall?
Sagacious Investor - at Seeking Alpha - Fri Apr 24, 7:02AM CDT
IDRA: 3.32 (-0.12), ISIS: 66.37 (-1.38)
Isis Pharmaceuticals' ISIS-TTR Effective in Extension Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 5:21PM CDT
Isis Pharmaceuticals, Inc. (ISIS) announced positive data from an extension study on ISIS-TTR for familial amyloid polyneuropathy.
BIIB: 401.71 (-28.57), ISIS: 66.37 (-1.38), AVEO: 1.92 (-0.08), GSK: 46.59 (+0.28)
Alnylam Strengthens Its Clinical Case Once Again
Stephen Simpson, CFA - at Seeking Alpha - Thu Apr 23, 10:27AM CDT
ALNY: 119.01 (+0.29), ISIS: 66.37 (-1.38), PFE: 35.27 (-0.09), ALXN: 180.08 (-4.50)
Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis
PR Newswire - Wed Apr 22, 3:06PM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive data from an ongoing open-label extension (OLE) study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). FAP patients completing the ongoing Phase 3 study are eligible to enroll in this OLE study in which all patients receive ISIS-TTRRx. An analysis conducted on the first group of patients to reach three months of treatment in the OLE study showed a reduction in transthyretin (TTR) protein levels up to 92 percent with a median reduction of 78 percent compared to patients' baseline TTR levels at entry into the Phase 3 study. Patients continue to be enrolled as they complete dosing in the Phase 3 study. These data will be presented today at the American Academy of Neurology meeting in Washington, DC.
ISIS: 66.37 (-1.38)
How to Invest Money in Biotech
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 19, 1:02PM CDT
Source: Isis Pharmaceuticals, Facebook. I believe it goes without saying that the biotechnology sector is one of the most unique sectors in the stock market. Whereas most industries (and the companies within those industries) are valued based on...
ISIS: 66.37 (-1.38), GILD: 103.69 (-1.52), XBI: 233.86 (-2.86), CELG: 118.71 (+2.62)
Johnson & Johnson's Earnings: The Good, The Bad and The Ugly
George Budwell, The Motley Fool - Motley Fool - Thu Apr 16, 10:59AM CDT
After a stellar 2014, Johnson & Johnson 's stock has lagged behind the broader market this year: To gain some insight into this top healthcare stock's weakness so far in 2015, let's dig into the company's first-quarter earnings,...
ACHC: 72.60 (+0.22), JNJ: 101.08 (+0.62), PCYC: 256.59 (-0.51), ISIS: 66.37 (-1.38), SGEN: 37.14 (-0.36), GILD: 103.69 (-1.52), PFG: 51.62 (+0.31), ABBV: 66.07 (+1.82), PBYI: 222.10 (-6.35)
Top 50 Big Biotech Partnering and M&A Deal Trends Report 2015
M2 - Thu Apr 16, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxqgzt/top_50_big) has announced the addition of the "Top 50 Big Biotech Partnering and M&A Deal Trends" report to their offering. The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies. Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits: - Detailed partnering activity profiles for each of the top 50 big biotech companies - Over 300 charts showing a company's dealmaking activity since 2009, allowing quick identification potential partners - Partnering therapy focus revealed - Partnering activity since 2010 - number of deals per year - Full listing of partnering deals - Activity by deal type - Activity by industry sector - Activity by phase of development - Activity by technology type - Activity by therapeutic area - Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available - Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents - Understand the key deal terms the company has agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Big biotech top 50 dealmaking activity Chapter 3 - Top big biotech deals by value Chapter 4 - Submitting Opportunities to Big biotech Chapter 5 - Forthcoming big biotech partnering events Chapter 6 - Big Biotech Company Profiles - 30 of the 50 companies - Acorda Therapeutics - Actavis - Actelion - Alexion Pharmaceuticals - Alkermes - Allergan - Amgen - Bavarian Nordic - Biocon - Biogen Idec - BioMarin Pharmaceuticals - Celgene - CSL - Cubist - Genmab - Gilead Sciences - Isis Pharmaceuticals - Jaxx Pharmaceuticals - LFB Group - Medivation - PDL BioPharma - Pharmacyclics - Questcor Pharmaceuticals - Regeneron Pharmaceuticals - Roche - Salix Pharmaceuticals - SciClone Pharmaceuticals - Seattle Genetics - Shire - Vertex Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/dxqgzt/top_50_big
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), SLXP: 172.96 (+0.15), AMGN: 167.91 (-1.26), ACOR: 33.12 (-0.38), ALKS: 62.26 (-1.19), PDLI: 7.02 (-0.09), AGN: 240.22 (+2.88), ISIS: 66.37 (-1.38), GILD: 103.69 (-1.52), ALXN: 180.08 (-4.50), SCLN: 8.96 (-0.13), REGN: 480.09 (+0.01), CELGZ: 2.76 (-0.12)
3 Biotech Stocks That May Disappear Before 2020
Brian Orelli, Sean Williams, and George Budwell, The Motley Fool - Motley Fool - Wed Apr 15, 7:59AM CDT
Biotechs come and go. It's rare to see a biotech as old as Amgen , which is celebrating its 35th anniversary this year. Most biotechs get acquired, or fall short and go bankrupt long before then. We asked our team of biotech experts to find a...
INO: 10.35 (-0.25), ISIS: 66.37 (-1.38), AZN: 71.79 (-1.34), AMGN: 167.91 (-1.26), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22), EXEL: 3.08 (-0.02)
Critical Alerts For GoPro, Shire, Isis Pharmaceuticals, Whiting Petroleum and athenahealth Released By InvestorsObserver
PR Newswire - Fri Apr 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, SHPG, ISIS, WLL and ATHN.
GPRO: 44.73 (-1.35), WLL: 35.62 (-1.01), ISIS: 66.37 (-1.38), SHPG: 255.11 (-0.26), ATHN: 125.30 (+3.30)
Isis Pharmaceuticals to Present at Upcoming Investor Conferences
PR Newswire - Fri Apr 10, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:
ISIS: 66.37 (-1.38)
SmarTrend Watching for Potential Pullback in Shares of Isis Pharmaceuticals After 3.32% Gain
Comtex SmarTrend(R) - Thu Apr 09, 4:11PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $61.52 to a high of $64.10. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $63.90 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 66.37 (-1.38)
Jim Cramer -- If You're Not in Biotech for the Long Haul, Hit the Road
at The Street - Wed Apr 08, 5:14AM CDT
Today's a good day for all who own biotech to reassess. Ask yourself, do you know why you own it?
RH: 91.89 (+0.20), ISIS: 66.37 (-1.38), REGN: 480.09 (+0.01)
Isis And Durect Foray Into NASH; Durect Is The Better Bet
Clinically Sound Investor - at Seeking Alpha - Mon Apr 06, 7:23PM CDT
ISIS: 66.37 (-1.38), DRRX: 2.11 (-0.46)
Is Isis Pharmaceuticals (ISIS) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 7:53AM CDT
One stock that might be an intriguing choice for investors right now is Isis Pharmaceuticals as this security in the pharmaceutical space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
ISIS: 66.37 (-1.38)
ISIS Pharmaceuticals (ISIS) Strong On High Relative Volume Today
at The Street - Fri Mar 27, 9:05AM CDT
Trade-Ideas LLC identified ISIS Pharmaceuticals (ISIS) as a strong on high relative volume candidate
ISIS: 66.37 (-1.38)
Earnings Coverage - Isis Pharma
PR Newswire - Fri Mar 27, 7:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ISIS: 66.37 (-1.38)
'Mad Money' Lightning Round: Buy, Buy, Buy ConocoPhillips
at The Street - Thu Mar 26, 5:00AM CDT
Cramer likes Ryanair, Pfizer and MeadWestvaco but is avoiding Rovi Corporation, Five Prime Therapeutics and Avon Products.
RYAAY: 67.00 (+0.51), AVP: 9.02 (+0.03), ISIS: 66.37 (-1.38), MWV: 47.50 (+0.41), PFE: 35.27 (-0.09), IP: 53.67 (+0.79), COP: 67.51 (-0.75), VG: 4.90 (-0.04), URI: 96.64 (-1.89), ROVI: 19.48 (+0.18), FPRX: 24.20 (-0.26)
Pfizer Is An Outright Buy - Cramer's Lightning Round (3/25/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Thu Mar 26, 3:55AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 25. Bullish Calls: Isis Pharmaceuticals (NASDAQ: ISIS ): "My take is this: It is going to go even lower because it's part of the highest...
AVP: 9.02 (+0.03), PFE: 35.27 (-0.09), IP: 53.67 (+0.79), COP: 67.51 (-0.75), PCLN: 1,233.09 (+11.99), VG: 4.90 (-0.04), NFLX: 558.40 (-0.66), RYAAY: 67.00 (+0.51), ISIS: 66.37 (-1.38), MWV: 47.50 (+0.41), FPRX: 24.20 (-0.26), ROVI: 19.48 (+0.18), URI: 96.64 (-1.89)
Jim Cramer's 'Mad Money' Recap: This Market Has Gotten Too Hot
at The Street - Wed Mar 25, 7:13PM CDT
As Cramer predicted, biotechs have started to cool. What should investors do next? Nothing, he advises.
73.54 (+0.34), UTX: 116.16 (-1.10), KRFT: 87.57 (-0.81), PAH: 27.18 (-0.76), INTC: 32.08 (-0.27), PVH: 104.43 (-0.86), VG: 4.90 (-0.04), DFS: 58.39 (-0.28), RYAAY: 67.00 (+0.51), PAYX: 49.23 (-0.28), SONC: 30.83 (-0.21), MWV: 47.50 (+0.41), COST: 148.12 (+0.82), ABBV: 66.07 (+1.82), MMP: 82.31 (+0.61), REGN: 480.09 (+0.01), CSCO: 28.82 (+0.15), URI: 96.64 (-1.89), ROVI: 19.48 (+0.18), AVP: 9.02 (+0.03), KR: 71.70 (+0.77), FB: 81.53 (-0.88), IP: 53.67 (+0.79), PFE: 35.27 (-0.09), DIS: 109.53 (+0.53), COP: 67.51 (-0.75), AMGN: 167.91 (-1.26), WFC: 54.70 (-0.16), DENN: 11.69 (+0.05), CELG: 118.71 (+2.62), WWAV: 45.60 (-0.08), ISIS: 66.37 (-1.38), FPRX: 24.20 (-0.26) Isis Pharmaceuticals Reports Phase I Data on Lipid Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 3:51PM CDT
Isis Pharmaceuticals, Inc. (ISIS) announced encouraging results from a phase I study on pipeline candidate ISIS-ANGPTL3Rx.
ISIS: 66.37 (-1.38), ANIP: 70.26 (-1.52), HZNP: 31.75 (+0.97), SNY: 51.75 (-0.01)
